Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

ACAT inhibitors from Sankyo

June 14, 1996

Hyperlipidemia treatment from Takeda

June 14, 1996

Ligand/Wyeth-Ayerst collaboration extended

June 14, 1996

Phase I trial to begin for aerosolized form of osteoporosis drug

June 14, 1996

Sanofi Winthrop launches tiludronic acid

June 14, 1996

La Jolla Cancer Research Foundation claims mammalian trophinin

June 7, 1996

Zomacton, human growth hormone now available in Italy

June 7, 1996

Torii and Asahi Brewery report aldose reductase inhibitors

June 7, 1996

NN-42-1007: First potent and selective hepatic glycogen phosphorylase inhibitor

June 7, 1996

Sanguine's PHER-02 development

June 7, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...